The Economics of Orphan Drug Policy in the US
- 1 November 1995
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 8 (5), 374-384
- https://doi.org/10.2165/00019053-199508050-00002
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The use--and misuse--of growth hormone.1995
- Patents in the public interestNature, 1994
- Back to the Future: Biotech Product Sales 1983–1993Bio/Technology, 1993
- Knocking on Opportunity's WindowBio/Technology, 1993
- Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?1992
- Cost of innovation in the pharmaceutical industryJournal of Health Economics, 1991
- Orphan Products: Origins, Progress, and ProspectsAnnual Review of Pharmacology and Toxicology, 1991
- The Orphan Drug Act. The first 7 yearsJAMA, 1991
- A closer look at the returns and risks of pharmaceutical R&DJournal of Health Economics, 1986